Co-founder and CEO of NanoVax Therapeutics, Griffin Kane, completed the Massachusetts Biomedical Initiatives (MBI) SPARK 2026 program. This free program supports early-stage life science entrepreneurs developing innovative breakthrough science and technologies and prepares later-stage companies to successfully raise capital.
Kane is a postdoctoral researcher in biomedical engineering working in the Atukorale lab. He is a 2024 recipient of the IALS Translational Graduate Research Assistantship. NanoVax Therapeutics is a biotechnology company developing next-generation nanoparticle-based cancer vaccines to transform outcomes for patients with aggressive, treatment-resistant tumors.
Categories: